Clinical Trial Update: Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bevacizumab with irinotecan or temozolomide for recurrent or refractory glioblastoma multiforme or gliosarcoma; study complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme
• Gliosarcoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)
• Temozolomide (Temozolomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Glioblastoma, Adult Gliosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2013-05-01